Conart Engineers has secured a significant civil construction work order worth approximately ₹15.41 crore from Apothecon Pharmaceuticals. According to the latest disclosure filed with BSE, the contract was received on Tuesday, May 26, 2026, and involves civil construction work for LVAPI-6 services at PO Dabhasa, Padra, Vadodara district, Gujarat. The project is scheduled to be executed within 12 months from the date of the purchase order, with the contract value excluding GST and potentially varying depending on final layout modifications or additional work awarded during project execution.
The company has confirmed that neither its promoters nor promoter group entities have any interest in the awarding authority. As reported by Business Standard, the transaction does not qualify as a related-party transaction, ensuring proper regulatory compliance. Conart Engineers is engaged in providing engineering, procurement, and construction (EPC) and contracting services for industrial, commercial, and infrastructure projects, with experience across manufacturing facilities, industrial infrastructure, and specialized projects requiring technical execution capabilities.
Following the contract announcement, shares of Conart Engineers rose 4.04% to close at ₹110 on the BSE, according to latest trading data. The stock touched a high of ₹112.45 and low of ₹102.90 before ending near the upper end of the day's trading range. As of 3:30 PM IST on May 27, 2026, the stock was trading at ₹110.00, up ₹4.27 from the previous close of ₹105.73. The positive market response reflects investor confidence in the company's ability to secure and execute large-scale construction projects in the pharmaceutical sector, with the order adding fresh business visibility and strengthening Conart's presence in the pharmaceutical infrastructure segment.
